- Home
- Pathology Industry
- Human Genome Sciences Market and Forecasts, May 2013
Industries
- Pathology (10)
- Drug Discovery and Development (3)
- Pharmaceutical (3)
- Biopharmaceutical (2)
- Biotechnology (2)
-
- Genomics (2)
- Banking (1)
- Biological Therapy (1)
- Blood Supply, Tissue Banking and Transplantation (1)
- Investment Banking (1)
- Managed Care (1)
- Nanotechnology (1)
- Soft Drink (1)
- Therapy (1)
Top countries
Publication dates
All regions
data types
- All
- Company Data (324)
- Industry Data
- Country Data (19)
Human Genome Sciences Market and Forecasts, May 2013
You might be interested in: antibody, merger and acquisition, monoclonal antibody, more »
industry reports
country reports
» Download Public Reports
1-10 of 29 reports for Human Genome Sciences
Pharmaceutical Sector Overview
- Industry report
- August 2011
- 36 pages
... genome sciences and daiichi company overview 6 key strengths maximizing value by bringing mabs to clinical poc phase iii phase ii pre-clinical phase i approval/ marketing bio ...
- Industries: Pathology
World Multiple Myeloma Business Overview
- Industry report
- June 2011
- 31 pages
... Ph. I multiple myeloma Tb-403 Milestone payment from roche Tb-402 Positive ph. Ii data reported human genome science product development alliance Bi-204 Ph. Ii ...
Multiple Myeloma Business Overview
- Industry report
- March 2011
- 26 pages
... Ii data reported human genome science product development alliance Bi-204 Ph. Ii and milestone payment from genentech Q1: tb-403 Start ph.Ib/ii glioblastoma Q1: tb-403 ...
- Industries: Pathology
Pharmaceutical in The United States and Australia : Innovation and Technology Trends
- Industry report
- February 2011
- 36 pages
... Us$500m Us$1b (based on human genome sciences ip valuation for their lupus drug in development) lupus market Lupus is a disease where the body S immune system attacks all organs and often ...
- Industries: Pathology
- Countries: United States, Australia, World
Bioprocessing Market (bioprocessing, monoclonal antibody, vaccine) in The United States
- Industry report
- October 2012
- 40 pages
... Manager, amgen inc. Mitigating risk in the raw material supply chain c ase s tud y unpublished d ata craig malzahn, director, supply chain, human genome sciences, inc. Applying process analytics ...
- Industries: Biopharmaceutical
- Countries: United States
U.S. Human Genome Market : Innovation and Technology Trends
- Industry report
- April 2012
- 31 pages
... Over seven years by the investment company healthcare investment corporation to establish The institute for genomic research (Tigr), a nonprofit research institute Sister company human genome ...
- Industries: Genomics
- Countries: United States
Multiple Sclerosis Sector Overview (multiple sclerosis, breast cancer, alzheimer's disease)
- Industry report
- January 2011
- 36 pages
... human genome sciences/glaxo) was introduced in 4/2011 as the first novel lupus erythematodes treatment in 50 years. During clinical development, benlysta failed to reach clinical endpoints in phase ii ...
- Industries: Pathology
Pharmaceutical in The United States and Australia : Innovation and Technology Trends
- Industry report
- February 2011
- 36 pages
... Approx. Us$500m Us$1b (based on human genome sciences ip valuation for their lupus drug in development) for personal use only lupus market Lupus is a disease where the body S immune system ...
- Industries: Pathology
- Countries: United States, Australia, World
Pharmaceutical Industry Overview
- Industry report
- March 2012
- 26 pages
... Including roche, genentech, bayer, human genome sciences and daiichi 25 thank you 26 ...
- Industries: Pathology
Pharmaceutical Industry Overview
- Industry report
- May 2011
- 38 pages
... Pipeline is at the brink of value inflection points Business model and technology platform vald through numerous partnerships including roche, genentech, bayer, human genome sciences and daiichi ...
- Industries: Pathology
Reportlinker.com © Copyright 2013. All rights reserved.
